Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Michelson, D. Articles by the Fluoxetine Panic Disorder Study Group, Search for Related Content PubMed Citation Articles by Michelson, D. Articles by the Fluoxetine Panic Disorder Study Group, Panic Disorder Antidepressants Anxiolytics

Outcome Assessment and Clinical Improvement in Panic Disorder: Evidence From a Randomized Controlled Trial of Fluoxetine and Placebo

Objective:Although panic attacks account for only a portion of the morbidity of panic disorder and panic attack frequency assessments are unreliable, studies of drug efficacy in panic disorder have generally used reduction in panic attack frequency as the primary measure of improvement. The authors studied the efficacy of fluoxetine treatment in panic disorder and measured the relative contributions of changes in symptoms to overall improvement.Method:Patients with a diagnosis of panic disorder (N=243) were randomly assigned to treatment with 10 or 20 mg/day of fluoxetine or placebo. Primary outcome measures were change in panic attack frequency and clinician-rated Clinical Global Impression improvement scores. Other assessments included a panic attack inventory, clinician-rated and patient-rated versions of the Panic and Phobic Disorder Change Scale, a phobia rating scale, the Hamilton Anxiety Rating Scale, the 21-item Hamilton Depression Rating Scale, and the Sheehan Disability Scale. Correlations were determined between outcomes in individual symptom domains and overall clinical outcome.Results:Fluoxetine, particularly the 20-mg/day dose, was associated with more improvement than was placebo in patients with panic disorder across multiple symptom measures, including global improvement, total panic attack frequency, phobic symptoms, and functional impairment. Global improvement was most highly correlated with reductions in overall anxiety and phobic symptoms and least correlated with reduction in panic attacks. Fluoxetine treatment for panic disorder was well tolerated, with a safety profile consistent with that observed for fluoxetine in other disorders.Conclusions:These data provide support for the efficacy and safety of fluoxetine treatment in reducing panic attacks, phobic symptoms, anxiety, and depressive symptoms in patients with panic disorder. Reductions in panic attack frequency in subjects given either fluoxetine or placebo were less closely related to overall clinical improvement than reductions in phobic avoidance, anxiety, depressive symptoms, and functional impairment, suggesting that outcome measures in this disorder should be more broadly based. Am J Psychiatry 1998; 155: 1570-1577

This article has been cited by other articles:

				D. S. Baldwin, I. M. Anderson, D. J. Nutt, B. Bandelow, A. Bond, J. R. T. Davidson, J. A. den Boer, N. A. Fineberg, M. Knapp, J. Scott, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology J Psychopharmacol, November 1, 2005; 19(6): 567 - 596. [Abstract] [PDF]

				M. W. Otto, K. S. Tuby, R. A. Gould, R. Y.S. McLean, and M. H. Pollack An Effect-Size Analysis of the Relative Efficacy and Tolerability of Serotonin Selective Reuptake Inhibitors for Panic Disorder Am J Psychiatry, December 1, 2001; 158(12): 1989 - 1992. [Abstract] [Full Text] [PDF]

				D. MICHELSON, C. ALLGULANDER, K. DANTENDORFER, A. KNEZEVIC, D. MAIERHOFER, V. MICEV, V. R. PAUNOVIC, I. TIMOTIJEVIC, N. SARKAR, L. SKOGLUND, et al. Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: Randomised, placebo-controlled trial The British Journal of Psychiatry, December 1, 2001; 179(6): 514 - 518. [Abstract] [Full Text] [PDF]

				A. Scott, A. Davidson, and K. Palmer Antidepressant drugs in the treatment of anxiety disorders Advan. Psychiatr. Treat., July 1, 2001; 7(4): 275 - 282. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 1998 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us